logo
  Join        Login             Stock Quote

Mylan Launches Generic Version of Epivir? Film Coated Tablets in the UK and Italy, its First Generic ARV Launch in Europe

Wednesday, June 6, 2012 9:36 AM


PITTSBURGH, POTTERS BAR, England, and MILAN, June 6, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its UK and Italy-based subsidiaries have launched Lamivudine Film Coated Tablets, 150 mg and 300 mg. This product is the generic version of GlaxoSmithKline's Epivir® Tablets, indicated as part of antiretroviral (ARV) combination therapy for the treatment of HIV-infected adults and children. This is the first generic HIV treatment to be available from Mylan in Europe.

Mylan CEO Heather Bresch commented: "As one of the world's leading providers of affordable ARVs, Mylan has a long history of contributing to the fight against HIV/AIDS across the developing world. We are excited that we can now bring our passion and experience in this important area to the European markets with the launch of Lamivudine, further delivering on our commitment to providing high quality and affordable medicines to patients around the world."

Didier Barret, Mylan's EMEA President, added: "We are very proud to launch our first ARV treatment in the European market, starting with hospitals in the UK and Italy. Our strong corporate commitment and expertise in the HIV space will support our continued development of a full HIV treatment portfolio in Europe."

Lamivudine Tablets had sales of approximately 3.4 million euros (2.6 million pounds Sterling) in the UK and sales of approximately 12.5 million euros in Italy for the 12 months ending March 31, 2012, according to IMS Health.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

(Source: PR Newswire )
(Source: Quotemedia)

Advertisement
Advertisement



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.